Home > Oncology > ASCO 2019 > Breast Cancer > Endocrine Therapy plus Ribociclib Yields Overall Survival Advantage in HR+/HER2-negative Breast Cancer

Endocrine Therapy plus Ribociclib Yields Overall Survival Advantage in HR+/HER2-negative Breast Cancer

Presented By
Dr Sara A. Hurvitz, University of California, Los Angeles, Jonsson Comprehensive Cancer Centre
Conference
ASCO 2019
Trial
Phase 3, MONALEESA-7

Medical writer: Jasenka Piljac Žegarac, PhD

Significantly longer overall survival (OS) was observed in women treated with endocrine therapy (ET) plus ribociclib, compared with women treated with ET alone, in the phase III MONALEESA-7 trial of premenopausal women with HR+/HER2-negative advanced breast cancer (ABC). This is the first study demonstrating significantly longer OS in patients treated with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor plus ET combination, compared to ET alone, as initial endocrine-based therapy.

“MONALEESA-7 was the first phase III trial with a CDK4/6 inhibitor [conducted] exclusively in premenopausal patients,” said Sara A. Hurvitz, MD, of the University of California, Los Angeles, Jonsson Comprehensive Cancer Centre, on June 4 (Abstract LBA1008).

A total of 672 premenopausal women with HR+/HER2-negative ABC who had not received ET for metastatic disease or who had received up to one prior line of chemotherapy were rand...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on